Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
| Period | What was disclosed | |
|---|---|---|
| FY 2025 network vaccine doses | 20-F supply chain | 389 million vaccine doses and 1.64 billion packs of medicines delivered by the manufacturing network. No Shingrix or Arexvy split. |
| FY 2025 Gavi doses | 20-F global health | 99 million doses to lower-income countries in 2025. Cumulative Gavi supply over 1.2 billion doses (floor). |
| FY 2025 Gavi brand doses | 20-F global health | Approximately 4 million Cervarix, 8 million RTS,S/AS01 malaria, around 44 million Synflorix (21 Gavi-eligible countries, lowest price), 43 million Rotarix (26 Gavi-eligible plus 4 former Gavi countries). |
| FY 2025 UNICEF oral polio | 20-F global health | Around 55 million oral polio vaccine doses supplied through UNICEF in 2025. |
| Pandemic influenza contracts | 20-F health security | HERA, Canada, US, and WHO contracts for Adjupanrix and Arepanrix together could provide at least 200 million doses if WHO declares an influenza pandemic (floor, not 2025 shipments). |
| FY 2025 Shingrix US coverage | 20-F and FY 2025 results | 44% of about 120 million US adults recommended to receive Shingrix have been vaccinated, up 4 percentage points versus 12 months earlier. Not a dose shipment figure. |
| Q2 2025 Shingrix US coverage | Q2 2025 results (IQVIA) | US cumulative immunisation rate 42%, IQVIA through end of Q1 2025. Shingrix launched in 56 countries. Ex-US was 72% of Q2 2025 global Shingrix sales. |
| FY 2025 Shingrix reach | FY 2025 results | Launched in 61 countries, 29 with public funding. Markets outside the US were 66% of 2025 global Shingrix sales (2024: 56%). Top-10 ex-US markets around 10% average immunisation rate. |
| Q1 2026 Shingrix US coverage | Q1 2026 results | US cumulative immunisation rate 45%, up 4 percentage points versus 12 months earlier. 29 of 61 launched countries had public funding. Top-10 ex-US markets around 11%. |
| Q2 2026 Shingrix US coverage | Q2 2026 results | US cumulative immunisation rate 45%, up 3 percentage points versus 12 months earlier. Top-10 ex-US markets around 12%, with higher uptake in funded cohorts. |
| FY 2025 Arexvy access | FY 2025 results | Approved in 69 markets. 21 countries had national RSV vaccination recommendations for older adults. 9 countries, including the US, had reimbursement programmes at year end. No Arexvy dose count printed. |
Glaxo Wellcome and SmithKline Beecham complete the merger that creates GlaxoSmithKline (27 Dec 2000). The vaccines P&L (Rixensart, Belgium) is inside this combination.
FDA licenses Shingrix on 20 Oct 2017 for adults 50+. AS01 adjuvanted recombinant zoster. This becomes GSK's largest vaccine and 66% ex-US by 2025.
FDA approves Arexvy, first adult RSV vaccine. Wall Street priced an annual franchise. ACIP later refused that frame.
ACIP RSV: all adults 75+, risk-based 60-74, not annual. Arexvy falls from £1.238B (2023) toward ~£0.6B.
FY 2025 vaccines £9.157B. Shingrix £3.558B with 66% ex-US as US immunization hits 44%. Meningitis £1.583B. Arexvy £593M.